Veracyte Announces First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- European stocks rise as markets stabilise, dollar set for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Caterpillar names Derrick York to lead Resource Industries
Veracyte, Inc (VCYT) PT Lowered to $26 at Needham & Company
May 4, 2022 6:51 AM EDTNeedham & Company analyst Mike Matson lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $26.00 (from $31.00) while maintaining a Buy rating following earnings.
The analyst commented, "VCYT's 1Q22 revenue and EPS beat consensus. Organic revenue growth (excluding estimated revenue from Decipher and... More
Veracyte (VCYT) Tops Q1 EPS by 4c
May 3, 2022 4:40 PM EDTVeracyte (NASDAQ: VCYT) reported Q1 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $67.8 million versus the consensus estimate of $62.32 million.
GUIDANCE:
Veracyte sees FY2022 revenue of $265-275 million, versus the consensus of $270... More



